Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00121563
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2005-07-20
Brief Title:
Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect
Sponsor:
National Institute of Nursing Research NINR
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Evaluation of TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect
Status:
COMPLETED
Status Verified Date:
2006-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the role of thalidomide a tumor necrosis factor TNF-alpha modulator on severe inflammation and relief of pain following extraction of wisdom teeth TNFs are substances that affect the pathways of pain This study involves an experimental group in which patients will be given thalidomide or a placebo an inactive substance a negative control group receiving the medication diazepam or a placebo and a positive control group receiving diazepam or ibuprofen
Patients who are males ages 16 to 35 who are not allergic to aspirin or other nonsteroidal anti-inflammatory drugs known as NSAIDs sulfites or certain anesthetics and who in good health may be eligible for this study Females are not eligible owing to the risks that thalidomide presents to unborn children To minimize the risk of fetal malformations male patients who participate must use a condom during sexual intercourse for 4 weeks following the study and must not donate blood for 4 weeks
The medications used in the study will be given 1 hour before surgery Then after the wisdom teeth are removed a small piece of tubing will be placed into both sides of the patients mouth where the teeth were removed Every 20 minutes for the next 6 hours the researchers will collect inflammatory fluid from the tubing to measure for changes in anti-inflammatory action If they request pain relievers patients will receive the medication ketorolac Toradol used for short-term treatment of moderately severe acute pain Side effects of thalidomide include fatigue dizziness and rash The use of ibuprofen and ketorolac may include the risk of gastrointestinal ulcers and bleeding Diazepam can cause involuntary muscle movements and drowsiness as well as dizziness lasting for up to 24 hours after it has been used as sedation Patients will be instructed not to try to walk alone or to try to drive a vehicle during that period Other risks related to participation in this study include those usually experienced with removal of wisdom teeth-that is pain and swelling bruising from insertion of the sedative into a vein if needed possible infection at the extraction site prolonged bleeding and numbness
Benefits from participating are having wisdom teeth removed at no cost as well as close monitoring before and after surgery Results from the study may help people in the future by improving the management of pain following surgery
Patients who are males ages 16 to 35 who are not allergic to aspirin or other nonsteroidal anti-inflammatory drugs known as NSAIDs sulfites or certain anesthetics and who in good health may be eligible for this study Females are not eligible owing to the risks that thalidomide presents to unborn children To minimize the risk of fetal malformations male patients who participate must use a condom during sexual intercourse for 4 weeks following the study and must not donate blood for 4 weeks
The medications used in the study will be given 1 hour before surgery Then after the wisdom teeth are removed a small piece of tubing will be placed into both sides of the patients mouth where the teeth were removed Every 20 minutes for the next 6 hours the researchers will collect inflammatory fluid from the tubing to measure for changes in anti-inflammatory action If they request pain relievers patients will receive the medication ketorolac Toradol used for short-term treatment of moderately severe acute pain Side effects of thalidomide include fatigue dizziness and rash The use of ibuprofen and ketorolac may include the risk of gastrointestinal ulcers and bleeding Diazepam can cause involuntary muscle movements and drowsiness as well as dizziness lasting for up to 24 hours after it has been used as sedation Patients will be instructed not to try to walk alone or to try to drive a vehicle during that period Other risks related to participation in this study include those usually experienced with removal of wisdom teeth-that is pain and swelling bruising from insertion of the sedative into a vein if needed possible infection at the extraction site prolonged bleeding and numbness
Benefits from participating are having wisdom teeth removed at no cost as well as close monitoring before and after surgery Results from the study may help people in the future by improving the management of pain following surgery
Detailed Description:
The proposed investigation is a randomized double-blind placebo and positive-controlled clinical study to evaluate the role of the cytokine tumor necrosis factor alpha TNF-alpha modulator thalidomide in acute inflammation and analgesia The analgesic effect of thalidomide a putative TNF-alpha modulator will be evaluated using a model of tissue injury the oral surgery model Briefly healthy males referred for third molar extraction will undergo the surgical extraction of third molars using standard surgical methods At the completion of the surgical procedure a microdialysis probe will be placed under the mucogingival flap previously elevated for the surgical procedure and subjects will be observed for pain over the course of six hours following surgery Thalidomide or control will be administered one hour prior to surgery Tissue levels of pro-inflammatory cytokines and inflammatory mediators will be measured at time intervals postoperatively concomitant with pain measurements Pain will be assessed postoperatively over the course of six hours Demonstration of amelioration of pain is the primary outcome measure changes in levels of tissue mediators will be taken as evidence of an acute anti-inflammatory effect of thalidomide Based on our previous work with the fusion protein etanercept TNFRfc which specifically binds TNF-alpha and prevents its interaction with cellular receptors similar changes in the inflammatory cascade and clinical endpoints of inflammation may provide insight into the activity of thalidomide on acute inflammation and its clinical sequela pain
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 05-NR-0193 | None | None | None |